Rani Therapeutics Holdings, Inc. (RANI) Stock Analysis
A live, multi-source view of Rani Therapeutics Holdings, Inc. (RANI): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity; Chugai Pharmaceutical Co., Ltd. to commercialize the Chugai Product combining Chugai's Compound, which is in development for hemophilia, and the RaniPill HC oral delivery device for use in humans; and has a research and development collaboration with PegBio Co., Ltd.
Sector: Healthcare · Industry: Biotechnology · United States · 69 employees · ranitherapeutics.com
Key statistics · as of 2026-09-06
As of 2026-09-06, Rani Therapeutics Holdings, Inc. (RANI) had a market capitalization of $121.6M (forward -4.6) and a beta of 0.71; the shares traded in a 52-week range of $0.45 – $3.87 (73.0% over the year).
- Market cap
- $121.6M
- Enterprise value
- $57.3M
- Forward P/E
- -4.6
- Price / book
- 2.48
- EPS (trailing)
- $-0.13
- EPS (forward)
- $-0.19
- Payout ratio
- 0.0%
- 52-week range
- $0.45 – $3.87
- 52-week change
- 73.0%
- Beta
- 0.71
- Average volume
- 790,555
- Shares outstanding
- 115.4M
- Short % of float
- 7.26%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Rani Therapeutics Holdings, Inc. (RANI) last closed at $0.82 (the last completed close before that scan).
Technicals at the scan: RSI 47 (neutral territory), price -3.3% versus its 20-day average, 20-day versus 50-day average spread +6.2%, MACD histogram -0.01.
Sentiment inputs: StockTwits 95% bullish; analyst consensus score 81/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of RANI; corporate insiders filed 2 buys and 2 sells (3 distinct filers, latest disclosure 2026-07-23). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Talat Imran (1B/1S), Mir A. Imran (1B/0S), Alireza Javadi (0B/1S). Who is trading what
RapidTradeView pick record
RANI has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Rani Therapeutics Holdings, Inc. (RANI) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell RANI.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.